99 related articles for article (PubMed ID: 24590864)
21. Comparison of ras-responsive gene enhancers in pancreatic tumor cells that express either wild-type or mutant K-ras.
Wilder PJ; Chakravarthy H; Hollingsworth MA; Rizzino A
Biochem Biophys Res Commun; 2009 Apr; 381(4):706-11. PubMed ID: 19254697
[TBL] [Abstract][Full Text] [Related]
22. The farnesyltransferase inhibitor LB42708 suppresses vascular endothelial growth factor-induced angiogenesis by inhibiting ras-dependent mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signal pathways.
Kim CK; Choi YK; Lee H; Ha KS; Won MH; Kwon YG; Kim YM
Mol Pharmacol; 2010 Jul; 78(1):142-50. PubMed ID: 20406854
[TBL] [Abstract][Full Text] [Related]
23. Simultaneous Covalent Modification of K-Ras(G12D) and K-Ras(G12C) with Tunable Oxirane Electrophiles.
Yu Z; He X; Wang R; Xu X; Zhang Z; Ding K; Zhang ZM; Tan Y; Li Z
J Am Chem Soc; 2023 Sep; 145(37):20403-20411. PubMed ID: 37534597
[TBL] [Abstract][Full Text] [Related]
24. The effect of sodium nitroprusside on survival and stress signaling in PC12 rat phaeochromocytoma cells expressing a dominant negative RasH mutant protein.
Bátor J; Varga J; Szeberényi J
Biochem Cell Biol; 2013 Aug; 91(4):230-5. PubMed ID: 23859017
[TBL] [Abstract][Full Text] [Related]
25. Targeting RAS signalling pathways in cancer therapy.
Downward J
Nat Rev Cancer; 2003 Jan; 3(1):11-22. PubMed ID: 12509763
[TBL] [Abstract][Full Text] [Related]
26. The C-terminal end of R-Ras contains a focal adhesion targeting signal.
Furuhjelm J; Peränen J
J Cell Sci; 2003 Sep; 116(Pt 18):3729-38. PubMed ID: 12890755
[TBL] [Abstract][Full Text] [Related]
27. Chemical biology tools for regulating RAS signaling complexity in space and time.
van Hattum H; Waldmann H
Chem Biol; 2014 Sep; 21(9):1185-95. PubMed ID: 25237862
[TBL] [Abstract][Full Text] [Related]
28. Targeting oncogenic KRasG13C with nucleotide-based covalent inhibitors.
Goebel L; Kirschner T; Koska S; Rai A; Janning P; Maffini S; Vatheuer H; Czodrowski P; Goody RS; Müller MP; Rauh D
Elife; 2023 Mar; 12():. PubMed ID: 36972177
[TBL] [Abstract][Full Text] [Related]
29. Covalent Guanosine Mimetic Inhibitors of G12C KRAS.
Xiong Y; Lu J; Hunter J; Li L; Scott D; Choi HG; Lim SM; Manandhar A; Gondi S; Sim T; Westover KD; Gray NS
ACS Med Chem Lett; 2017 Jan; 8(1):61-66. PubMed ID: 28105276
[TBL] [Abstract][Full Text] [Related]
30. Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4+ and CD8+ T cell responses.
Abrams SI; Stanziale SF; Lunin SD; Zaremba S; Schlom J
Eur J Immunol; 1996 Feb; 26(2):435-43. PubMed ID: 8617315
[TBL] [Abstract][Full Text] [Related]
31. Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations.
Abrams SI; Khleif SN; Bergmann-Leitner ES; Kantor JA; Chung Y; Hamilton JM; Schlom J
Cell Immunol; 1997 Dec; 182(2):137-51. PubMed ID: 9514698
[TBL] [Abstract][Full Text] [Related]
32. Sugar-based inhibitors of Ras activation: biological activity and identification of Ras-inhibitor binding interface.
Di Domizio A; Peri F
Enzymes; 2013; 33 Pt A():95-116. PubMed ID: 25033802
[TBL] [Abstract][Full Text] [Related]
33. Approaches to Ras signaling modulation and treatment of Ras-dependent disorders: a patent review (2007--present).
Sacco E; Spinelli M; Vanoni M
Expert Opin Ther Pat; 2012 Nov; 22(11):1263-87. PubMed ID: 23009088
[TBL] [Abstract][Full Text] [Related]
34. Knock-in of mutant K-ras in nontumorigenic human epithelial cells as a new model for studying K-ras mediated transformation.
Konishi H; Karakas B; Abukhdeir AM; Lauring J; Gustin JP; Garay JP; Konishi Y; Gallmeier E; Bachman KE; Park BH
Cancer Res; 2007 Sep; 67(18):8460-7. PubMed ID: 17875684
[TBL] [Abstract][Full Text] [Related]
35. Design and characterization of a new class of inhibitors of ras activation.
Colombo S; Peri F; Tisi R; Nicotra F; Martegani E
Ann N Y Acad Sci; 2004 Dec; 1030():52-61. PubMed ID: 15659780
[TBL] [Abstract][Full Text] [Related]
36. Spatiotemporal Analysis of K-Ras Plasma Membrane Interactions Reveals Multiple High Order Homo-oligomeric Complexes.
Sarkar-Banerjee S; Sayyed-Ahmad A; Prakash P; Cho KJ; Waxham MN; Hancock JF; Gorfe AA
J Am Chem Soc; 2017 Sep; 139(38):13466-13475. PubMed ID: 28863262
[TBL] [Abstract][Full Text] [Related]
37. Silencing of SPRY1 triggers complete regression of rhabdomyosarcoma tumors carrying a mutated RAS gene.
Schaaf G; Hamdi M; Zwijnenburg D; Lakeman A; Geerts D; Versteeg R; Kool M
Cancer Res; 2010 Jan; 70(2):762-71. PubMed ID: 20068162
[TBL] [Abstract][Full Text] [Related]
38. Oncogenic K-ras segregates at spatially distinct plasma membrane signaling platforms according to its phosphorylation status.
Barceló C; Paco N; Beckett AJ; Alvarez-Moya B; Garrido E; Gelabert M; Tebar F; Jaumot M; Prior I; Agell N
J Cell Sci; 2013 Oct; 126(Pt 20):4553-9. PubMed ID: 23943869
[TBL] [Abstract][Full Text] [Related]
39. Progress on Covalent Inhibition of KRAS(G12C).
Westover KD; Jänne PA; Gray NS
Cancer Discov; 2016 Mar; 6(3):233-4. PubMed ID: 26951837
[TBL] [Abstract][Full Text] [Related]
40. Ras ubiquitination: coupling spatial sorting and signal transmission.
Rodriguez-Viciana P; McCormick F
Cancer Cell; 2006 Apr; 9(4):243-4. PubMed ID: 16616329
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
